These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36542644)

  • 1. Long-term benefits for lower socioeconomic groups by improving bowel screening participation in South Australia: A modelling study.
    Lal A; Gao L; Tan E; McCaffrey N; Roder D; Buckley E
    PLoS One; 2022; 17(12):e0279177. PubMed ID: 36542644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study.
    Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K
    Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment.
    Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K
    PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The projected health and economic impact of increased colorectal cancer screening participation among Canadians by income quintile.
    Adegbulugbe AA; Farah E; Ruan Y; Yong JHE; Cheung WY; Brenner DR
    Can J Public Health; 2024 Jun; 115(3):384-394. PubMed ID: 38502494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling cost-effective strategies for minimising socioeconomic inequalities in colorectal cancer screening outcomes in England.
    Thomas C; Mandrik O; Whyte S
    Prev Med; 2022 Sep; 162():107131. PubMed ID: 35803353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults.
    Sharma T
    Public Health; 2020 May; 182():70-76. PubMed ID: 32179290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colonoscopy surveillance following adenoma removal to reduce the risk of colorectal cancer: a retrospective cohort study.
    Cross AJ; Robbins EC; Pack K; Stenson I; Kirby PL; Patel B; Rutter MD; Veitch AM; Saunders BP; Little M; Gray A; Duffy SW; Wooldrage K
    Health Technol Assess; 2022 May; 26(26):1-156. PubMed ID: 35635015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term risk of colorectal cancer after screen-detected adenoma: Experiences from a Danish gFOBT-positive screening cohort.
    Bjerrum A; Lindebjerg J; Andersen O; Fischer A; Lynge E
    Int J Cancer; 2020 Aug; 147(4):940-947. PubMed ID: 31894860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Equity of colorectal cancer screening: which groups have inequitable participation and what can we do about it?
    Ward PR; Javanparast S; Wilson C
    Aust J Prim Health; 2011; 17(4):334-46. PubMed ID: 22112702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Colorectal cancer screening in rural and remote areas: analysis of the National Bowel Cancer Screening Program data for South Australia.
    Martini A; Javanparast S; Ward PR; Baratiny G; Gill T; Cole S; Tsourtos G; Aylward P; Jiwa M; Misan G; Wilson C; Young GP
    Rural Remote Health; 2011; 11(2):1648. PubMed ID: 21585228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget Impact Analysis of Against Colorectal Cancer In Our Neighborhoods (ACCION): A Successful Community-Based Colorectal Cancer Screening Program for a Medically Underserved Minority Population.
    Kim B; Lairson DR; Chung TH; Kim J; Shokar NK
    Value Health; 2017 Jun; 20(6):809-818. PubMed ID: 28577699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios.
    Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D
    PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of cancers and advanced adenomas in asymptomatic participants in colorectal cancer screening: a cross-sectional study.
    Schult AL; Botteri E; Hoff G; Randel KR; Dalén E; Eskeland SL; Holme Ø; de Lange T
    BMJ Open; 2021 Jul; 11(7):e048183. PubMed ID: 34210732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing.
    van der Meulen MP; Toes-Zoutendijk E; Spaander MCW; Dekker E; Bonfrer JMG; van Vuuren AJ; Kuipers EJ; van Kemenade FJ; van Velthuysen MF; Thomeer MGJ; van Veldhuizen H; de Koning HJ; Lansdorp-Vogelaar I; van Leerdam ME
    PLoS One; 2022; 17(2):e0264067. PubMed ID: 35176116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential for tailored screening to reduce bowel cancer mortality for Aboriginal and Torres Strait Islander peoples in Australia: Modelling study.
    Lew JB; Feletto E; Worthington J; Roder D; Canuto K; Miller C; D'Onise K; Canfell K
    J Cancer Policy; 2022 Jun; 32():100325. PubMed ID: 35560263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends and inequities in colorectal cancer screening participation in Ontario, Canada, 2005-2011.
    Honein-AbouHaidar GN; Baxter NN; Moineddin R; Urbach DR; Rabeneck L; Bierman AS
    Cancer Epidemiol; 2013 Dec; 37(6):946-56. PubMed ID: 23702337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Socioeconomic position and participation in colorectal cancer screening.
    Frederiksen BL; Jørgensen T; Brasso K; Holten I; Osler M
    Br J Cancer; 2010 Nov; 103(10):1496-501. PubMed ID: 20959827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
    Hathway JM; Miller-Wilson LA; Jensen IS; Ozbay B; Regan C; Jena AB; Weinstein MC; Parks PD
    J Med Econ; 2020 Jun; 23(6):581-592. PubMed ID: 32063100
    [No Abstract]   [Full Text] [Related]  

  • 19. The relative effectiveness of fecal immunochemical test-based colorectal cancer screening to detect adenomas and cancer in different demographic and socioeconomic groups. A nationwide cohort study.
    Larsen MB; Søborg B; Njor SH; Jensen TM; Ingeholm P; Andersen B
    Eur J Cancer Prev; 2022 Nov; 31(6):489-496. PubMed ID: 35485399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knowledge of, attitudes toward, and barriers to participation of colorectal cancer screening tests in the Asia-Pacific region: a multicenter study.
    Koo JH; Leong RW; Ching J; Yeoh KG; Wu DC; Murdani A; Cai Q; Chiu HM; Chong VH; Rerknimitr R; Goh KL; Hilmi I; Byeon JS; Niaz SK; Siddique A; Wu KC; Matsuda T; Makharia G; Sollano J; Lee SK; Sung JJ;
    Gastrointest Endosc; 2012 Jul; 76(1):126-35. PubMed ID: 22726471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.